| Literature DB >> 17659946 |
James M Backes1, Patrick M Moriarty, Janelle F Ruisinger, Cheryl A Gibson.
Abstract
Statins possess an excellent safety profile and are generally well tolerated when administered in the standard once-daily dosing regimen. A small percentage of patients however, discontinue therapy because of adverse events such as myalgias. The investigators describe 8 patients with previous intolerance to daily statin dosing and examine their responses to once-weekly rosuvastatin therapy. In conclusion, once-weekly rosuvastatin may be a feasible and effective option for patients previously intolerant to once-daily statin dosing.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17659946 DOI: 10.1016/j.amjcard.2007.03.059
Source DB: PubMed Journal: Am J Cardiol ISSN: 0002-9149 Impact factor: 2.778